Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate for prevention of pneumonia and meningitis in Gambian infants.
Background In developing countries, pneumonia and meningitis due to Haemophilus influenzae type b (Hib) are common in children under age 12 months and the mortality from meningitis is high.
Protein-polysaccharide conjugate vaccines have brought Hib disease under control in industrialised countries.
We did a double-blind randomised trial in The Gambia to assess the efficacy of a Hib conjugate vaccine for the prevention of meningitis, pneumonia, and other invasive diseases due to Hib.
Methods Between March, 1993, and October, 1995,42848 infants were randomly allocated the conjugate vaccine Hib polysaccharide tetanus protein (PRP-T) mixed with diphtheria-tetanus-pertussis vaccine (DTP), or DTP alone at age 2 months, 3 months, and 4 months.
Children who presented with signs of invasive Hib were investigated by blood culture and, where appropriate, by lumbar puncture, chest radiograph, or percutaneous lung aspirate.
Children were followed up for between 5 and 36 months.
Findings The median ages at which children received the study vaccine were 11 weeks, 18 weeks, and 24 weeks. 83% of children enrolled received all three doses of vaccine. 17 cases of culture-positive Hib pneumonia, 28 of Hib meningitis, and five of other forms of invasive Hib disease were detected amongst the study children. (...)
Mots-clés Pascal : Haemophilus influenzae, Pasteurellaceae, Bactérie, Vaccination, Prévention, Pneumonie, Epidémiologie, Randomisation, Méningite, Effet conjugaison, Tétanos, Bactériose, Infection, Enfant, Homme, Gambie, Afrique, Immunoprophylaxie, Education santé, Appareil respiratoire pathologie, Poumon pathologie, Système nerveux pathologie, Système nerveux central pathologie
Mots-clés Pascal anglais : Haemophilus influenzae, Pasteurellaceae, Bacteria, Vaccination, Prevention, Pneumonia, Epidemiology, Randomization, Meningitis, Conjugation effect, Tetanus, Bacteriosis, Infection, Child, Human, Gambia, Africa, Immunoprophylaxis, Health education, Respiratory disease, Lung disease, Nervous system diseases, Central nervous system disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0299380
Code Inist : 002B05A02. Création : 15/07/1997.